Nuvectis Pharma, Inc. (NVCT)
23.73
-1.46
(-5.80%)
USD |
NASDAQ |
Aug 28, 16:00
23.62
-0.12
(-0.48%)
After-Hours: 20:00
Nuvectis Pharma Cash from Operations (Quarterly) : -4.531M for June 30, 2026
Cash from Operations (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -4.531M |
| March 31, 2026 | -6.511M |
| December 31, 2025 | -3.974M |
| September 30, 2025 | -4.494M |
| June 30, 2025 | -3.367M |
| March 31, 2025 | -4.174M |
| December 31, 2024 | -2.465M |
| September 30, 2024 | -2.404M |
| June 30, 2024 | -3.02M |
| March 31, 2024 | -4.358M |
| December 31, 2023 | -3.85M |
| Date | Value |
|---|---|
| September 30, 2023 | -3.244M |
| June 30, 2023 | -4.083M |
| March 31, 2023 | -4.777M |
| December 31, 2022 | -3.516M |
| September 30, 2022 | -4.424M |
| June 30, 2022 | -2.543M |
| March 31, 2022 | -3.076M |
| December 31, 2021 | -1.067M |
| September 30, 2021 | -4.426M |
| June 30, 2021 | -4.011M |
| March 31, 2021 | 0.00 |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Decoy Therapeutics, Inc. | -2.652M |
| Unicycive Therapeutics, Inc. | -7.604M |
| ACADIA Pharmaceuticals, Inc. | 100.78M |
| Alnylam Pharmaceuticals, Inc. | 326.72M |
| Anika Therapeutics, Inc. | -0.684M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Financing (Quarterly) | 1.561M |
| Free Cash Flow | -19.51M |
| Free Cash Flow Per Share (Quarterly) | -0.193 |
| Free Cash Flow to Equity (Quarterly) | -4.531M |
| Free Cash Flow to Firm (Quarterly) | -4.531M |
| Free Cash Flow Yield | -3.45% |